Neurocrine Biosciences (NBIX) Positive Data of Its NBI-98854

Neurocrine Biosciences, Inc. (NBIX)

The abundance of prescription drugs and Over the Counter (OTC) medications now flooding the market has produced a rapidly expanding number of unintended (but nonetheless foreseeable) problems with respect to adverse drug reactions.

Each year, more than 9.6 million adverse drug reactions occur in older Americans.

The drugs responsible for the most serious adverse reactions in older adults are tranquilizers, sleeping pills, and other mind-affecting drugs; cardiovascular drugs such as high blood pressure drugs, digoxin, and drugs for abnormal heart rhythms; and drugs for treating intestinal problems.

Tardive Dyskinesia is one of the muscular side effects of anti-psychotic drugs. Essentially, prolonged exposure to antipsychotic treatment (which is necessary for many persons who have chronic schizophrenia) is the major reason that Tardive Dyskinesia occurs in an individual.

Tardive dyskinesia is characterized by involuntary, repetitive movements of the extremities: lip smacking, grimacing, tongue protrusion, facial movements or blinking, puckering and pursing of the lips, or involuntary movements of the limbs. These symptoms are rarely reversible and there is currently no approved treatment.

NBIX reported that its NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study.

The Kinect 2 Study was a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide

In this study NBI-98854 was generally safe and well tolerated.

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. NBI-98854, developed in NBIX 's laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines, thereby reducing the likelihood of "off target" side effects.

NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion.

NBIX is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders.

More about Neurocrine Biosciences, Inc. (NBIX) at www.neurocrine.com .

**

Crown Equity Holdings Inc. (CRWE)

"Social networking" has been around forever. It's the simple act of expanding the number of people you know by meeting your friends' friends, their friends' friends and so on.

A social networking service is an online service, platform, or site that focuses on facilitating the building of social networks or social relations among people who, for example, share interests, activities, backgrounds, or real-life connections.

CRWE is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market.

CRWE is currently developing a social networking service and phone app, CRWE Network ( CRWE-PR.com ), that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada.

CRWE ‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.pennyomega.com/disclaimer